Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Amyloid precursor protein secretase Stories

2014-02-20 08:31:52

- Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, Pa., Feb. 20, 2014 /PRNewswire/ -- Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and advancing novel, small molecule, best-in-class compounds, announced today that it has earned a $14 million milestone payment from Boehringer Ingelheim (BI) for BI's initiation of a Phase 1 clinical trial in the companies' beta-secretase...

2013-08-08 09:39:19

Though one might think the brains of people who develop Alzheimer's disease (AD) possess building blocks of the disease absent in healthy brains, for most sufferers, this is not true. Every human brain contains the ingredients necessary to spark AD, but while an estimated 5 million Americans have AD – a number projected to triple by 2050 – the vast majority of people do not and will not develop the devastating neurological condition. For researchers like...

2013-06-24 10:37:13

Researchers in Berlin and Munich, Germany and Oxford, United Kingdom, have revealed that a protein well known for its role in Alzheimer's disease controls spindle development in muscle and leads to impaired movement in mice when the protein is absent or treated with inhibitors. The results, which are published in The EMBO Journal, suggest that drugs under development to target the beta-secretase-1 protein, which may be potential treatments for Alzheimer's disease, might produce unwanted side...

Alzheimer's Disease Drug Stopped Mid-Trial
2013-06-17 05:08:38

Lee Rannals for redOrbit.com - Your Universe Online Eli Lilly & Co has ended a clinical trial for an Alzheimer's disease drug during the middle of the study after patients showed abnormal liver biochemical tests. The company announced last week that it would be putting a halt to its LY2886721 drug trial. LY2886721, the code-name for the drug, was designed to inhibit beta secretase, which contributes to the buildup of amyloid plaque in the brain that is believed to cause Alzheimer's....

2013-06-13 16:27:02

Decision does not impact other Lilly Alzheimer's compounds in development INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the progression of Alzheimer's disease. The decision to terminate the study was due to abnormal liver biochemical tests. Clinical study investigators have...

2013-05-15 23:03:02

MetLife Foundation today announced the recipients of its 2013 Awards for Medical Research in Alzheimer´s Disease: Yueming Li, Ph.D., member and professor, Sloan-Kettering Institute and director and professor, Graduate Program in Pharmacology, Weill Medical College of Cornell University, and Lennart Mucke, M.D., director, Gladstone Institute of Neurological Disease, Joseph B. Martin Distinguished Professor of Neuroscience and professor of Neurology, University of California, San...

2012-12-04 12:25:28

NEW YORK, Dec. 4, 2012 /PRNewswire-USNewswire/ -- The Fisher Center for Alzheimer's Research Foundation (ALZinfo.org) today announced it has received the highest 4-star rating for the second consecutive year from Charity Navigator's, the nation's premier charity evaluator. Only 17% of the charities rated by Charity Navigator have received 2 or more consecutive 4-star evaluations, indicating that Fisher Center for Alzheimer's Research Foundation outperforms most other charities in America....

2012-12-03 20:47:58

Scientists from VIB and KU Leuven have discovered a new target molecule for the development of a treatment against Alzheimer's disease. There is currently no cure for this disease. Many candidate drugs fail because they also target proteins essential to life. This discovery from Leuven could form a target for a treatment against Alzheimer's disease with fewer side effects and that suppresses the very first symptoms of the disease. This research will be published in the leading journal Nature...

2012-07-18 10:26:32

CAMBRIDGE, Mass., July 18, 2012 /PRNewswire/ -- Satori Pharmaceuticals, a company dedicated to developing life-changing therapeutics for Alzheimer's disease (AD), announced today that its lead compound, a gamma-secretase modulator (GSM), is efficacious in preclinical models following single or multi-day dosing. This oral presentation, as well as two poster presentations related to the characteristics of Satori's GSMs, was presented at the Alzheimer's Association International Conference...

shutterstock_104922437
2012-07-13 07:06:17

Connie K. Ho for redOrbit.com - Your Universe Online 5 million. That´s the number of people in the U.S. suffering from Alzheimer´s disease, according to a recent CNN article. Scientists recently announced that they had discovered a gene that fights Alzheimer´s. This is a positive step forward as the gene could help develop treatments to fight the disorder. In the journal Nature, researchers explained how the gene that caused an early form of Alzheimer´s could also be...